Novartis Pharma B.V.
Location
Noord-Holland
Founded
1948-02-10
Website
Risk Signals
21161 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Drugs, Drug Proprietaries, and Druggists' Sundries), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Novartis Pharma B.V.
Live alerts from global media, monitored by Business Radar
2023-01-19 (moneycontrol.com)
MC Analysis I Why India’s cardiology pharma market is expecting a major disruption this year
With a blockbuster heart failure drug Vymada going off-patent this month, its much cheaper generic versions by a number of drug makers are set to hit the market in India and several other countries.
Read more
2020-11-18 (fiercepharma.com)
NICE's thumbs-up on Lilly's migraine med Emgality leaves rivals from Novartis and Teva in the dust
England's drug cost watchdogs have not been gentle on companies marketing hot but expensive new CGRP inhibitors to treat migraine headaches. | England 's National Institute of Health and Care Excellence recommended Eli Lilly 's CGRP inhibitor Emgality to treat migraines after limiting the use of
Read more
2020-07-02 (fiercepharma.com)
Amgen's Enbrel fends off biosimilar threat—and heads toward blockbuster superstardom
With Amgen’ s top line facing pressure for quite some time from biosimilar versions of flagship drugs like Epogen and Neulasta, the prospect that it could lose exclusivity on its top-selling product| The U.S. Federal Appeals Court upheld a 2019 ruling that kept Novartis’ biosimilar rival to Enbrel
Read more
(fiercepharma.com)
Novartis' latest attempt to fend off MSN's Entresto generic falls short on appeal |
Novartis' latest effort to block a generic challenger to blockbuster heart med Entresto has come up short, this time in a federal appeals court. | The U.S. Court of Appeals for the Federal Circuit sided with a prior ruling that denied Novartis' motion seeking an injunction to prevent MSN's generic rival from launching.
Read more